NCT06782984Recruiting
Drug Response Testing and Repurposing Using Glioblastoma Organoid
Patient-derived Organoids As Predictive Models for Drug Response Testing and Repurporsing in Glioblastoma Therapy
Source: ClinicalTrials.gov · Last updated 20 Jan 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The aim of this observational study, based on a prospectively collected cohort, is to evaluate the prognostic value of patient-derived organoids in predicting responses to conventional and repurposing drugs, including temozolomide, in patients with primary or recurrent glioblastoma. The primary question is whether the patient's response to temozolomide is recapitulated in their corresponding patient-derived glioblastoma organoid (GBO). Patient drug responses are evaluated using survival data, while GBO drug responses are assessed through a drug-response testing platform utilizing cell viability assays. Additionally, this platform is used to explore the potential application of various chemotherapeutic agents.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 150 (estimated)
- First submitted
- 6 Jan 2025
- Start date
- 18 Aug 2021
- Primary completion date
- Dec 2028
- Lead sponsor
- Chungnam National University Hospital
- Diseases
- Glioblastoma, Childhood cancers
- NCT number
- NCT06782984
What you commit to
- Study type: Observational
- Planned participants: 150
- From 18 Aug 2021 to the primary completion date, Dec 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- patients who are not underwent concurrent chemoradiation therapy (CCRT) following surgery
Other
- failed to obtain MRI scan after CCRT
- patients refusal
Who the study is looking for
- primary or recurrent glioblastoma
- patients treated with standard treatment including surgery and temozolomide based chemoradiation therapy
- sufficient tumor sample is available for organoid culture
Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Chungnam National University Hospital Coordinator of this site? Confirm its status | Daejeon | South Korea | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.